Personalized Cancer Vaccines Market Report 2026

The personalized cancer vaccines market size has grown strongly in recent years. It will grow from $256.65 billion in 2025 to $273.05 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to advances in cancer genomics, unmet need in oncology treatments, limitations of traditional cancer therapies, growth in immunotherapy research, increased funding for cancer research.

The personalized cancer vaccines market size is expected to see strong growth in the next few years. It will grow to $350.3 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to expansion of personalized medicine adoption, increasing cancer incidence rates, progress in neoantigen discovery, rising collaboration between biotech firms, supportive regulatory frameworks. Major trends in the forecast period include rising focus on personalized immunotherapy, increasing use of genomic tumor profiling, expansion of therapeutic cancer vaccines, growing integration with precision oncology, higher clinical trial activity in cancer vaccines.

The rising incidence of cancer is anticipated to fuel expansion in the personalized cancer vaccine market. Cancer encompasses a range of diseases marked by uncontrolled cell proliferation that can infiltrate nearby tissues and metastasize to distant body sites. This surge in cancer cases stems from aging demographics, shifts in lifestyle, environmental factors, and advances in detection methods. Personalized cancer vaccines aid oncology treatment by providing customized formulations based on individual tumor antigens, enhancing the immune system's capacity to detect and destroy malignant cells. For instance, in July 2024, the Australian Institute of Health and Welfare (AIHW), an Australia-based government body, reported that cancer diagnoses in Australia climbed from 160,570 in 2022 to 164,694 in 2023, reflecting a notable annual uptick. Thus, the growing burden of cancer is propelling the personalized cancer vaccine market forward.

Major companies in the personalized cancer vaccine market are prioritizing the development of cutting-edge therapeutic options, like personalized immunotherapy tailored to individual patient tumor mutations, to boost treatment accuracy and patient outcomes. Personalized immunotherapy involves bespoke cancer therapies that leverage a patient's unique genetic and tumor mutation data, often administered via dendritic cell vaccines or neoantigen-specific platforms, to trigger a customized immune attack on cancer cells. For example, in August 2024, UCLA Health, a US-based healthcare provider, initiated a pioneering clinical trial for a personalized cancer vaccine targeting the H3 G34 mutation in diffuse hemispheric gliomas; it employs dendritic cells to provoke an immune response against the RNA alterations from this aggressive mutation, providing a hopeful new avenue for adolescents and young adults facing scarce options and low survival rates.

In June 2025, BioNTech SE, a Germany-based biotechnology company, acquired CureVac N.V. for an undisclosed amount. Through this acquisition, BioNTech seeks to bolster its research, development, manufacturing, and commercialization efforts in mRNA-based cancer immunotherapy, while advancing its oncology strategy. CureVac N.V., a Germany-based company, specializes in developing personalized cancer vaccines.

Major companies operating in the personalized cancer vaccines market are Moderna Inc., CureVac AG, BioNTech SE, Genentech Inc., Merck & Co. Inc., GlaxoSmithKline plc, Achilles Therapeutics Plc, Evaxion Biotech AS, Geneos Therapeutics Inc., ISA Pharmaceuticals BV, VAXIMM GmbH, EpiVax Therapeutics Inc., Personalis Inc., Catalent Inc., Gritstone bio Inc., Neon Therapeutics Inc., Nouscom AG, Vaccitech plc, Agenus Inc., Transgene SA.

North America was the largest region in the personalized cancer vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized cancer vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs for imported sequencing tools, bioinformatics hardware, reagents, and biologic components used in personalized cancer vaccine development. These impacts are most evident in advanced markets where precision oncology programs depend on highly specialized global suppliers. Rising tariff related expenses have added pressure to research budgets and early stage manufacturing costs. This has influenced commercialization timelines and partnership strategies for personalized vaccine platforms. However, tariffs are also encouraging domestic innovation, local technology development, and localized manufacturing capabilities for next generation cancer vaccines over the long term.

The personalized cancer vaccines market research report is one of a series of new reports that provides personalized cancer vaccines market statistics, including personalized cancer vaccines industry global market size, regional shares, competitors with a personalized cancer vaccines market share, detailed personalized cancer vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the personalized cancer vaccines industry. This personalized cancer vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Personalized cancer vaccines are treatments customized to a patient's distinct tumor characteristics, designed to activate their immune system against cancer cells. They enhance the body's capacity to identify and combat particular cancer types, which may boost treatment effectiveness and lower the risk of relapse.

The primary categories of personalized cancer vaccines consist of preventive and therapeutic types. Preventive cancer vaccines aim to safeguard against infections or conditions that could potentially cause cancer. They target multiple cancer types, such as lung cancer, breast cancer, colorectal cancer, leukemia, prostate cancer, cervical cancer, and glioblastoma, via diverse mechanisms including tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), somatic mutations in cancer pharmacogenomics, pharmacogenomics related to genomic polymorphisms, and additional approaches. Delivery occurs through various administration routes, like injectables and others, across different settings including hospitals, clinics, and more.

The personalized cancer vaccines market consists of sales of patient-specific vaccines, neoantigen-based therapies, dendritic cell-based vaccines and peptide-based immunotherapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.